Floatz logo

Octreotide Pamoate

Cholangio Carcinoma

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Phase 4 / ApprovedActive
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Cholangio Carcinoma cohort.

Asset / SponsorPhaseRating
Solu-Cortef
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 4B

Same molecule, other indications

Octreotide Pamoate is also rated in:

diarrheal diseaseDormant
BB
Indicative ·
71 / 100
View asset →
cirrhosis of liverDormant
BB
Indicative ·
71 / 100
View asset →
esophageal varicesDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →